骨巨细胞瘤中RunX2表达及对骨质调控的临床研究

摘要

目的 探讨核心结合因子(RunX2)表达与骨巨细胞瘤(GCT)临床病理特征之间的关系.方法 选择GCT标本58例,分别按照肿瘤恶性程度、肿瘤病理分级、是否侵犯软组织及是否伴发病理性骨折分组,应用免疫组织化学染色技术分析并比较RunX2在不同组表达水平的差异.结果 RunX2在恶性GCT组织内的表达水平显著高于良性GCT组织(P＜0.05);RunX2的表达随着GCT组织分级的升高而升高(P＜0.05);有软组织侵犯状况的GCT组织内的表达RunX2水平高于无软组织侵犯GCT组织(P＜0.05);而伴发病理性骨折的GCT组RunX2表达量高于无伴发病理性骨折组(P＜0.05).结论 RunX2的表达量与GCT严重程度有关.%Objective To explore the relationship between the RunX2 expression and the clinicopathological features in bone giant cell tumor(GCT).Methods Fifty-eight specimens of GCT were selected and grouped according to the malignant degree,tumor pathological grade,whether having soft tissue invasion and complicating pathological fracture.Then the immunohistochemical staining technique was used to analyze and compare the difference of RunX2 expression levels among different groups.Results The RunX2 expression level in malignant GCT tissues was significantly higher than that in benign GCT tissue(P＜0.05).RunX2 expression level was increased with the GCT tissue histological grade increase(P＜0.05).The expression level RunX2 in GCT tissue with soft tissue invasion was significantly higher than that in the GCT tissue without invasion(P＜0.05);the RunX2 expression level in GCT tissue with complicating pathologic fractures was significantly higher than that in the GCT tissue without complicating pathologic fractures(P＜0.05).Conclusion The RunX2 expression level is related to the severity of GCT.